Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
TuHURA Biosciences, Inc.
National Cancer Institute (NCI)
Mayo Clinic
Mayo Clinic
Tizona Therapeutics, Inc
Essen Biotech
Werewolf Therapeutics, Inc.
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Institut Curie
Transgene
BioInvent International AB
Eisai Inc.
TuHURA Biosciences, Inc.
Immuneering Corporation
NuCana plc
Medicenna Therapeutics, Inc.
BioAtla, Inc.
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
CJ Bioscience, Inc.
Immodulon Therapeutics Ltd
GI Innovation, Inc.
Salubris Biotherapeutics Inc
National Cancer Institute (NCI)
Pliant Therapeutics, Inc.
Eli Lilly and Company
University of California, San Francisco
Rutgers, The State University of New Jersey
Providence Health & Services
Seagen Inc.
Columbia University
Incyte Corporation
Merck Sharp & Dohme LLC